GHRH receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,500 people. Operating under a full-service model, the company also offers global central laboratory, imaging and ECG core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio. The company started trading stock as a public firm in 2016.
=== Ribosomal translocation === Macrolides, clindamycin and aminoglycosides (with all these three having other potential mechanisms of action as well), have evidence of inhibition of ribosomal translocation. Fusidic acid prevents the turnover of elongation factor G (EF-G) from the ribosome. Ricin inhibits elongation by enzymatically modifying an rRNA of the eukaryotic 60S ribosomal subunit.
Traditional harvesting of opium poppies to produce opiates involved the labor-intensive work of making shallow cuts in the immature fruits (seed pods) so that the latex would leak out and dry, then returning the following day to scrape off the dry latex, known as raw opium. Harvesting of poppy straw is an alternative, largely mechanized, method. The plants are allowed to mature fully, then a machine is used to harvest the entire field. The ripe poppy seeds are separated out by threshing and winnowing, and the remainder is poppy straw. Poppy straw usually consists of only the above ground parts of the plant, but the roots may be harvested as well. Some producers mow the plants high, so that the harvest consists almost entirely of the fruits (seed pods), omitting the stalks, leaves, and roots. Poppy straw is then processed in a manner similar to opium to extract opiates and other alkaloids (see: Morphine). Avoiding the labor-intensive harvesting of opium by hand was the topic of research for almost 100 years. This research was of notable interest in those countries where opium poppy was an important oilseed crop but where high labor costs made the harvesting of opium uneconomic. What was needed was a process that enabled commercial extraction of opiates from opium poppies directly rather than from (comparatively pure) opium. By the 1940s, commercial production of morphine from poppy straw had spread from Hungary to Poland and finally to most countries where poppies are grown on a large scale primarily for their seeds.
=== Periodic limb movement disorder === Selegiline has been studied in the treatment of periodic limb movement disorder (PLMD) in a single small open-label clinical study. It was reported to be effective as assessed by polysomnography, reducing periodic limb movements during sleep by about 60%. Selegiline has not been studied for the related condition restless legs syndrome (RLS) as of 2023. The drug has not been studied well enough in PLMD or RLS to be widely used in their treatment.
Hazard research is published: a systematic analysis estimates 4.71 million deaths were associated with bacterial antimicrobial resistance (AMR) in 2021, estimates the trends in AMR mortality since 1990, and finds AMR could cause 39 million deaths worldwide between 2025 and 2050 (16 Sep.), researchers publish data on the detection of over 3000 food contact materials (FCMs) in humans (17 Sep.), and a study finds 189 (21%) of potential breast carcinogens have been measured in FCMs, indicating at least 76 of these leach into foods of populations (24 Sep.).
Sources: en.wikipedia.org
== Traditional attributes == The bark is categorized in a traditional Chinese medicine counterpart of humorism, Wu Xing, as bitter and cold, affecting the kidney, urinary bladder and large intestine meridians. It is said "to clear heat and dry dampness", and "to reduce fire and release toxins".
In molecular biology, the condensation domain is a protein domain found in many multi-domain enzymes which synthesise peptide antibiotics. This domain catalyses a condensation reaction to form peptide bonds in non-ribosomal peptide biosynthesis. It is usually found to the carboxy side of a phosphopantetheine binding domain (pp-binding). It has been shown that mutations in the HHXXXDG sequence motif in this domain abolish activity suggesting this is part of the active site.
== Flow velocity == The solution of the equations is a flow velocity. It is a vector field—to every point in a fluid, at any moment in a time interval, it gives a vector whose direction and magnitude are those of the velocity of the fluid at that point in space and at that moment in time. It is studied in three spatial dimensions and one time dimension, and higher-dimensional analogues are studied in both pure and applied mathematics. Once the velocity field is calculated, other quantities of interest, such as pressure or temperature, may be found using dynamical equations and relations. This is different from what one normally sees in classical mechanics, where solutions are typically trajectories of the position of a particle or deflection of a continuum. Studying velocity instead of position makes more sense for a fluid, although for visualization purposes, one can compute various trajectories. In particular, the streamlines of a vector field, interpreted as flow velocity, are the paths along which a massless fluid particle would travel. These paths are the integral curves whose derivative at each point is equal to the vector field, and they can represent visually the behavior of the vector field at a point in time.
Christopher Marley (born 1969) is an artist, photographer, naturalist, and author who uses natural artifacts as his artistic medium. He is best known initially for his book Biophilia, and then for the traveling exhibit Exquisite Creatures that features his art.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.